Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?

Allergologia et Immunopathologia

Volumn 41, Issue 3, 2013, Pages 181-188

  Celik G E ^a   Erkekol, F O ^a   Aydin, O ^a   Demirel, Y S ^a   Misirligil, Z ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Alternative drugs; Aspirin hypersensitivity; Aspirin intolerance; Drug hypersensitivity; Drug provocation tests; Meloxicam; Nimesulide; NSAID cross reactivity; Predictive factors

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROVOCATION TEST; RETROSPECTIVE STUDY; URTICARIA;

ADULT; ANALGESICS, NON-NARCOTIC; ANGIOEDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BRONCHIAL SPASM; COMORBIDITY; CYCLOOXYGENASE 2 INHIBITORS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOLOGIC TESTS; LACTONES; MALE; PREDICTIVE VALUE OF TESTS; PYRAZOLES; RESPIRATORY HYPERSENSITIVITY; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SKIN TESTS; SULFONAMIDES; SULFONES; THIAZINES; THIAZOLES; UNNECESSARY PROCEDURES; URTICARIA;

EID: 84878114303     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2012.03.006     Document Type: Article

References (40)

1. çelik G., Pichler W., Adkinson N.F. Drug allergy. Middleton's allergy: principles and practice 2009, 1205-1226. Mosby/Elsevier, Philadelphia, PA. 7th ed. F.E.R. Simons (Ed.).
2. Bircher A.J. Approach to the patient with a drug hypersensitivity reaction-clinical perspectives. Drug hypersensitivity 2007, 352-365. Karger, Basel. W.J. Pichler (Ed.).
3. Brockow K., Romano A., Blanca M., Ring J., Pichler W., Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002, 57:45-51.
4. Aberer W., Bircher A., Romano A., Blanca M., Campi P., Fernandez J., et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003, 58:854-863.
5. Stevenson D.D., Szczeklik A. Clinical and pathological perspective on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006, 118:773-786.
6. Kowalski M.L. Aspirin-sensitive rhinosinusitis and asthma. Clin Allergy Immunol 2007, 19:147-175.
7. Mastalerz L., Setkowicz M., Szczeklik A. Mechanism of chronic urticaria exacerbation by aspirin. Curr Allergy Asthma Rep 2005, 5:277-283.
8. Kowalski M.L., Makowska J. Use of nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity: safety of cyclo-oxygenase-2 inhibitors. Treat Respir Med 2006, 5:399-406.
9. Global strategy for asthma management and prevention. National Institutes of Health publication. No:02-3659; 2003.
10. Andri L., Senna G., Betteli C., Givanni S., Scaricabarozzi I., Mezzelani P., et al. Tolerability of nimesulide in aspirin-sensitive patients. Ann Allergy 1994, 72:29-32.
11. Senna G.E., Passalacqua G., Andri G., Dama A.R., Albano M., Fregonese L., et al. Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs. Drug Saf 1996, 14:94-103.
12. Bavbek S., Celik G., Ediger D., Mungan D., Demirel Y.S., Misirligil Z. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance. J Asthma 1999, 36:657-663.
13. Karakaya G., Kalyoncu A.F. Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics. Allergol Immunopathol (Madr) 2000, 28:319-321.
14. Bavbek S., Celik G., Ozer F., Mungan D., Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma 2004, 41:67-75.
15. Quiralte J., Sáenz de San Pedro B., Florido J.J. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002, 89:63-66.
16. Pacor M.L., Di Lorenzo G., Biasi D., Barbagallo M., Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002, 32:397-400.
17. Perrone M.R., Artesani M.C., Viola M., Gaeta F., Caringi M., Quaratino D., et al. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 2003, 132:82-86.
18. Bavbek S., Celik G., Pasaoglu G., Misirligil Z. Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients. J Investig Allergol Clin Immunol 2006, 16:57-62.
19. Martín-García C., Hinojosa M., Berges P., Camacho E., García-Rodriguez R., Alfaya T. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol 2003, 13:20-25.
20. Celik G., Paşaoĝlu G., Bavbek S., Abadoĝlu O., Dursun B., Mungan D., et al. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma 2005, 42:127-131.
21. Liccardi G., Salzillo A., Piccolo A., Senna G., Piscitelli E., D'Amato M., et al. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs. Eur Ann Allergy Clin Immunol 2005, 37:50-53.
22. Roll A., Wüthrich B., Schmid-Grendelmeier P., Hofbauer G., Ballmer-Weber B.K. Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs. Swiss Med Wkly 2006, 28:684-690.
23. Domingo M.V., Marchuet M.J., Culla M.T., Joanpere R.S., Guadaño E.M. Meloxicam tolerance in hypersensitivity to nonsteroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 2006, 16:364-366.
24. Bavbek S., Dursun A.B., Dursun E., Eryilmaz A., Misirligil Z. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. Int Arch Allergy Immunol 2007, 142:64-69.
25. Göksel O., Aydin O., Misirligil Z., Demirel Y.S., Bavbek S. Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema. J Dermatol 2010, 37:973-979.
26. Sánchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 2005, 94:34-38.
27. Nettis E., Colanardi M.C., Ferrannini A., Vacca A., Tursi A. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005, 95:438-442.
28. Viola M., Quaratino D., Gaeta F., Caruso C., Valluzzi R., Romano A. Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2007, 143:103-108.
29. Colanardi M.C., Nettis E., Traetta P., Delle Donne P., Ferrannini A., Vacca A. Parecoxib as an alternative in COX-2 hypersensitivity. Int J Immunopathol Pharmacol 2008, 21:233-235.
30. Colanardi M.C., Nettis E., Traetta P., Daprile C., Fitto C., Aloia A.M., et al. Safety of parecoxib in patients with nonsteroidal anti-inflammatory drug-induced urticaria or angioedema. Ann Allergy Asthma Immunol 2008, 100:82-85.
31. Asero R. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. Ann Allergy Asthma Immunol 1999, 82:554-558.
32. Trombetta D., Imbesi S., Vita G., Isola S., Minciullo P.L., Saija A., et al. Possible link between history of hypersensitivity to a specific non-steroidal anti-inflammatory drug (NSAID) and positive results following challenge test to alternative NSAIDS. Arzneimittelforschung 2009, 59:410-414.
33. Astorello E.A., Zara C., Riario-Sforza G.G., Pravettoni V., Incorvaia C. Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs. Allergy 1998, 53:880-884.
34. Sánchez-Borges M., Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol 2000, 84:101-106.
35. Nizankowska-Mogilnicka E., Bochenek G., Mastalerz L., Swierczyńska M., Picado C., Scadding G., et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007, 62:1111-1118.
36. Celik G., Erkekol F.O., Bavbek S., Dursun B., Misirligil Z. Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance. Ann Allergy Asthma Immunol 2005, 95:33-37.
37. Nettis E., Colanardi M.C., Ferrannini A., Tursi A. Immune tolerance to drugs (II). Long-term tolerability of nimesulide in patients with NSAID hypersensitivity. Immunopharmacol Immunotoxicol 2004, 26:469-480.
38. Nettis E., Colanardi M.C., Ferrannini A., Tursi A. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005, 94:29-33.
39. Di Leo E., Aloia A.M., Nettis E., Cardinale F., Foti C., Distaso M., et al. Long-term tolerability of etoricoxib in patients with previous reactions to non-steroidal anti-inflammatory drugs. Int J Immunopathol Pharmacol 2009, 22:1131-1134.
40. Schneeweiss S., Glynn R.J., Avorn J., Solomon D.H. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol 2005, 58:98-102.